CanSino Biologics shares jumped 26% after its Shanghai unit agreed with DeepVise Bio to co-develop personalized mRNA cancer vaccines.
CanSino Biologics shares jumped 26% after its Shanghai unit agreed with DeepVise Bio to co-develop personalized mRNA cancer vaccines, thrusting the Chinese vaccine maker into the oncology mRNA race.
The partnership combines CanSino's mRNA vaccine technology with DeepVise Bio's tumor neoantigen discovery and design capabilities, the company said in a filing. The most recent analyst rating on the stock is a Buy with a HK$64.00 price target, according to TipRanks data.
CanSino is developing mRNA prophylactic vaccines and therapeutic biologics, including candidates for glioblastoma, rhabdomyosarcoma and cervical cancer, plus In Vivo CAR-related therapies, all at early stage. The stock rose HK$7.36 to close at HK$35.68, giving the company a market capitalization of HK$13.65 billion. Short selling reached HK$30.98 million, a 3.067% ratio.
The rally follows Moderna and Merck's positive Phase 3 results for a personalized mRNA cancer vaccine, which renewed investor interest in mRNA oncology platforms. The partnership could accelerate CanSino's therapeutic vaccine pipeline, though all programs remain at early stage and clinical data has not yet been disclosed.
mRNA Oncology Momentum Builds Across the Sector
The Moderna-Merck Phase 3 success has lifted the entire mRNA therapeutics space. Novavax, which uses its Matrix-M adjuvant technology, reported Q2 revenue of $56.7 million, beating consensus, and raised its full-year 2026 revenue guidance to $235 million-$275 million. The company holds $724 million in cash as of June 30, and its partnership with Sanofi is advancing regulatory alignment for a Phase 3 COVID-19-influenza combination trial that would trigger a $125 million milestone payment.
The sector-wide enthusiasm reflects a broader shift in how investors value mRNA platforms. While COVID-19 vaccines built the initial commercial case for mRNA technology, therapeutic applications in oncology represent a much larger addressable market. Moderna's personalized cancer vaccine, developed with Merck, targets tumor-specific mutations and demonstrated improved outcomes in the Phase 3 trial, according to the companies' announcement.
mRNA cancer vaccines work by delivering genetic instructions that train the immune system to recognize and attack tumor-specific antigens. Unlike traditional vaccines that prevent infectious disease, therapeutic cancer vaccines are designed to treat existing tumors by stimulating a targeted immune response. Personalized approaches, like the one CanSino and DeepVise Bio plan to develop, sequence a patient's tumor to identify neoantigens — mutated proteins unique to that cancer — and then design a vaccine tailored to those mutations.
CanSino's Pipeline and What's at Stake
CanSino's mRNA platform underpins its pipeline of preventive vaccines and therapeutic biologics. The company recently won NMPA approval for a new tetanus vaccine, and its Td5cp booster received priority review after NDA acceptance in China, expanding its adult vaccine portfolio beyond COVID-19 shots.
The personalized cancer vaccine market is drawing significant investment as mRNA technology moves beyond infectious disease. CanSino's partnership with DeepVise Bio puts it in competition with Moderna and BioNTech in therapeutic oncology, though its programs are considerably earlier stage. The company has not disclosed cash runway for its mRNA therapeutic programs.
CanSino shares, trading at a market cap of HK$13.65 billion, have surged on the partnership news and sector momentum. The analyst consensus is a Buy with a HK$64.00 target, implying roughly 79% upside from current levels. However, with all therapeutic programs at early stage and no clinical data disclosed, the valuation hinges on pipeline execution rather than near-term revenue. The company's established vaccine business, including the recently approved tetanus vaccine and Td5cp booster, provides a commercial foundation while the mRNA oncology programs develop.
This article is for informational purposes only and does not constitute investment advice.
